Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-420-4 | CAS number: 69430-40-6 DC 5067
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- May 26, 1988 - March 13, 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- α-trimethylsilanyl-ω-trimethylsiloxypoly[oxy(methyl-3-(2-(2-methoxypropoxy)propoxy)propylsilanediyl]-co-oxy(dimethylsilane))
- EC Number:
- 406-420-4
- EC Name:
- α-trimethylsilanyl-ω-trimethylsiloxypoly[oxy(methyl-3-(2-(2-methoxypropoxy)propoxy)propylsilanediyl]-co-oxy(dimethylsilane))
- Cas Number:
- 69430-40-6
- Molecular formula:
- Unspecified example: C18.3H46.8O5.8Si4.1
- IUPAC Name:
- 2,2,4,4,6,12,15-heptamethyl-6-[(trimethylsilyl)oxy]-3,5,10,13,16-pentaoxa-2,4,6-trisilaheptadecane
- Details on test material:
- Identification: DC 5067
Description: Clear, light brown liquid
Lot Number: AB 090122
Purity: >99%
Storage conditions: In the original container at room temperature in the dark
Stability under storage conditions: Stab1e
Expiry date: December 1, 1991
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Duration of exposure:
- 24 hours
- Doses:
- Dose level: 2000 mg/kg b.w.
Dose volume: 2.11 ml/kg b.w. - No. of animals per sex per dose:
- 5 males, 5 females
- Control animals:
- not required
Results and discussion
Effect levels
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Remarks on result:
- other: confidence limits n/a
Any other information on results incl. tables
MORTALITY
No mortality occurred during the study period.
OBSERVATIONS
NO clinical signs of ill health or behavioural changes were seen during the study.
All animals showed body weight gain over the study period.
TREATED SKIN ABNORMALITIES
No skin irritation was observed on the treated area during the study period.
PATHOLOGY
Macroscopic post mortem examination of the surviving animals at termination did not reveal any abnormalities that were not commonly noted among rats of this age and strain.
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The dermal LD50 value of DC 5067 in rats of either sex was established as exceeding 2000 mg/kg body weight.
- Executive summary:
This study was entitled "Assessment of acute dermal toxicity with DC 5067 in the rat". The purpose of this study was to assess the toxicity of the test article when administered to rats as a single dermal dose. The study was carried out in accordance with OECD Guideline No. 402, "Acute Dermal Toxicity" and EEC Directive 84/449/EEC, Part 8.3, "Acute Toxicity - Dermal".
DC 5067 was administered by dermal application, to five rats of each sex, at 2000 mg/kg body weight. Macroscopic examination was performed at the end of the experimental period.
No clinical signs of ill health or behavioural changes were seen during the study. All animals showed body weight gain over the study period. No skin abnormalities were observed on the treated area during the study period. Macroscopic post mortem examination of the surviving animals at termination did not reveal any abnormalities, that were not commonly noted among rats of this age and strain.
The dermal LD50 value of DC 5067 in rats of either sex was established as exceeding 2000 mg/kg body weight.
According to the EEC criteria for classification and labelling requirements for dangerous substances'(EEC Directive 83/467/EEC, Annex VI of the EEC Directive
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
